• Biotechnology Company
• About Syntaxin
• Biopharmaceutical Product Pipeline
• Biotech Research & Development
• Bio Tech News
• Contact Biopharmaceutical Firm

 

Syntaxin is a biopharmaceutical company focusing on the discovery and development of a novel class of recombinant proteins able to target a fundamental intracellular pathway of secretion to create medicines to treat chronic diseases.

The company was founded in 2005 to develop complex proteins that can be used as biopharmaceuticals to treat neurological, endocrine and proliferative (oncology) disorders.

The Company's biopharma product pipeline is based on exploiting the potent pharmacological properties of microbial proteins, notably clostridial neurotoxins.

 

Potential New Targets Syntaxin novel drugs target many areas for therapeutic benefit.

Treat Endocrine Diseases Syntaxin are developing new treatments to tackle neuroendocrine cancer.